BridgeBio Pharma, Inc. has 16 Schedule 13D or 13G filings on record since 2025-07-01. 4 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Janus Henderson Group Plc | 6.8% | 13,179,013 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Farallon Capital Management, L.L.C. | 5.5% | 10,743,063 | SCHEDULE 13G/A, 2026-08-03 | 2026-06-30 |
| Dapice Joshua J. | 5.2% | 10,226,063 | SCHEDULE 13G, 2026-05-29 | 2026-05-22 |
| Viking Global Investors LP | 5% | 9,792,219 | SCHEDULE 13D/A, 2026-07-10 | 2026-07-09 |
| BlackRock, Inc. | 4.96% | 9,733,762 | SCHEDULE 13G/A, 2026-07-27 | 2026-06-30 |
| KKR Genetic Disorder L.P. | 4.7% | 8,260,971 | SCHEDULE 13D/A, 2026-08-17 | 2026-08-13 |
| Neil Kumar | 4.6% | 9,282,982 | SCHEDULE 13G/A, 2026-04-16 | 2026-03-31 |
| T. Rowe Price Associates, Inc. | 1.1% | 885,042 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Purpose of Transaction (Item 4)
Viking Global Investors LP
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 5(c) of this Amendment No. 12 is incorporated by reference herein.Item 4 of the SCHEDULE 13D/A filed 2026-07-10
KKR Genetic Disorder L.P.
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Sale of Common Stock On August 13, 2026, KKR Genetic Disorder L.P., as a selling stockholder, and the Issuer entered into an underwriting agreement (the ''Underwriting Agreement'') with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC (the ''Representatives''), as the representatives of the several underwriters listed on Schedule I thereto (the ''Underwriters''), relating to an offering of 5,000,000 shares of Common Stock by KKR Genetic Disorder L.P. (the ''Offering''), and purchase by the Underwriters of the shares of Common Stock, at a net price to KKR Genetic Disorder L.P. of $77.415 per share. The Offering closed on August 17, 2026. The Offering was made pursuant to the Issuer's effective shelf registration statement on Form S-3ASR (File No. 333-297701), including the prospectus, dated July 24, 2026, as supplemented by a prospectus supplement, dated August 13, 2026, filed on August 14, 2026. Pursuant to the Underwriting Agreement, KKR Genetic Disorder L.P. entered into a lock-up agreement (the ''Lock-Up Agreement'') with the Underwriters pursuant to which it has agreed with the Underwriters, subject to certain exceptions, not to dispose of or hedge any of their Common Stock or securities convertible into or exchangeable for shares of Common Stock, during the period from August 13, 2026 continuing through the date 30 days after the date of the final prospectus …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-17; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-01 | Viking Global Investors LP | 9.8% | SCHEDULE 13D/A |
| 2025-07-29 | The Vanguard Group | 8.68% | SCHEDULE 13G/A |
| 2025-08-14 | Viking Global Investors LP | 9.7% | SCHEDULE 13D/A |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 1.1% | SCHEDULE 13G |
| 2025-11-14 | Viking Global Investors LP | 8.2% | SCHEDULE 13D/A |
| 2026-02-17 | Viking Global Investors LP | 6.8% | SCHEDULE 13D/A |
| 2026-02-17 | Janus Henderson Group Plc | 5.7% | SCHEDULE 13G |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-02 | Viking Global Investors LP | 6.1% | SCHEDULE 13D/A |
| 2026-04-16 | Neil Kumar | 4.6% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 6.8% | SCHEDULE 13G/A |
| 2026-05-29 | Dapice Joshua J. | 5.2% | SCHEDULE 13G |
| 2026-07-10 | Viking Global Investors LP | 5% | SCHEDULE 13D/A |
| 2026-07-27 | BlackRock, Inc. | 4.96% | SCHEDULE 13G/A |
| 2026-08-03 | Farallon Capital Management, L.L.C. | 5.5% | SCHEDULE 13G/A |
| 2026-08-17 | KKR Genetic Disorder L.P. | 4.7% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for BridgeBio Pharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.